Top 6 high-paying careers to pursue in the USA
Students around the world view pursuing higher studies in the United States as a pivotal step towards building a successful career. The US job market offers a wide range of opportunities, and it is important to secure a career that offers long-term growth, stability, and a strong return on investment (ROI).
While choosing a field of study should always align with one's interests and strengths, it is equally important to consider where that degree will take you in the job market. Career decisions become more informed when supported by real data on income trends, job outlook, and industry demand.
Using the recent data from the US Bureau of Labour Statistics (BLS), we have identified six careers that stand out for their high earning potential and sustained demand across various sectors.
These professions blend financial reward with long-term relevance, making them a practical choice for students planning to pursue their careers in the United States.
Physicians and surgeons
Physicians and surgeons top the list of high-paying American careers. The BLS reports a median wage of $239,200 (approximately ₹2 crore) or more annually for this group.
Subspecialties such as pediatric surgery, cardiology, orthopedic surgery, radiology, and anesthesiology can earn even higher average incomes, ranging from $300,000 to $450,810 (ranging from ₹2.5 crore to ₹3.8 crore).
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Brass Krishna Idols For Prosperity & Protection In Life
Luxeartisanship
Shop Now
Undo
The career demands years of study, including medical school, but the return is substantial. Graduates also benefit from strong job growth, with an expected 4 percent increase in employment over the next decade.
Dentists and orthodontists
Dental specialists such as orthodontists and oral and maxillofacial surgeons also rank among the highest earners. Median annual wages for dental specialists exceed $239,200 (approximately ₹2 crore), according to BLS data.
Aspiring dental professionals must complete a professional dental degree followed by advanced training in a chosen specialty. The demand for dental specialists continues to grow due to increased emphasis on preventive care and overall oral health, making it a financially and professionally rewarding career choice.
Psychiatrists
Psychiatrists are medical doctors who specialise in mental health. They earn a median annual wage of $239,200 (approximately ₹2 crore) as per the BLS.
Their role includes diagnosing and treating mental illnesses and prescribing medications. With increasing focus on mental health care and greater awareness around mental wellness, the need for qualified psychiatrists continues to rise steadily.
Nurse anesthetists
Nurse anesthetists are among the highest-paid nursing professionals. The BLS does not list them under physicians, but Medical specialists which earn median wages near $200,000 (approximately ₹1.67 crore) annually.
This role requires a master's or doctoral degree in nurse anesthesia and professional licensure. Although they work fewer hours than many doctors, their salaries remain competitive due to their critical role in healthcare delivery.
Computer and information systems managers
In the technology sector, leadership positions in information systems are highly lucrative. BLS data shows that these managers earn a median annual wage of $169,510 (approximately ₹1.42 crore) as of May 2024.
As companies continue to emphasise cybersecurity, and data management, demand for these professionals keeps growing. The field offers a clear pathway for students with degrees in computer science, information technology, or related fields.
Financial managers
Leadership roles in finance offer high earning potential and steady demand. Financial managers earn a median salary between $134,180 and $156,100 (approximately ₹1.12 crore to ₹1.30 crore) depending on the industry.
They are responsible for budgeting, financial planning, and investment management.
Students with degrees in finance, economics, or accounting can enter the field and later obtain credentials such as MBA to enhance career growth in sectors including banking, investment, or corporate finance.
Whether you are drawn to medicine, technology, or finance, these six careers offer strong earning potential and meaningful job prospects in the US Most careers listed require significant academic investment and professional certification. However, the financial rewards can be substantial. Students should research accredited university programs, licensure requirements and any practical training or internship options to align their academic journey with these promising career paths.
Is your child ready for the careers of tomorrow? Enroll now and take advantage of our early bird offer! Spaces are limited.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Weight-loss drug Wegovy starts at ₹17,345 in India
Mumbai: Wegovy (semaglutide), the popular weight-loss drug from Danish drug maker Novo Nordisk , is priced between '17,345 and '26,015 across dosages in India. The company announced at its launch that the easy-to-administer once-a-weekly pen-filled injectable will have the advantage of convenient dosing. The drug will be available in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg) and will be prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE). Vikrant Shrotriya, MD, Novo Nordisk India, said obesity is a chronic disease and a national epidemic. "Wegovy is a transformative therapeutic solution with the convenience of a world-class, state-of-the-art pen device," he noted. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Нов таблет с Android Pro 14 Murreice Купете сега Undo Ambrish Mithal, chairman and head, endocrinology and diabetes, Max Healthcare , said although the price of Wegovy is not within the reach of the Indian masses, the potential for the drug is huge. Live Events Over time, he said, the cardiovascular benefit of Wegovy 2.4 mg is an important addition to the weight loss benefits. It is clinically proven to reduce cardiac events by 20%, both in people suffering from overweight/obesity with pre-existing heart disease. The drug can be prescribed for patients with BMI over 30 and those with BMI above 27 and pre-existing co-morbidities. Bariatric surgeon Mufazzal Lakdawala told ET that weight-loss drugs are proving to be the game-changers and they have just unlocked the potential for obese patients. He said the new age weight loss drugs could potentially complement bariatric surgery for patients beyond BMI of 45-50 as a weight-loss option. Compared to Wegovy, Mounjaro's 2.5 mg and 5 mg vials, which are also given on a weekly basis, are priced at '14,000 to '17,500 for a month's dose.
Time of India
an hour ago
- Time of India
Novo Nordisk's Wegovy debuts in India: How it works, who it's for, and how much it costs
Source: iStock In a major development for India's fast-growing anti-obesity drug market, Novo Nordisk on Tuesday officially launched Wegovy, its highly anticipated weight-loss medication, marking a direct challenge to Eli Lilly's already available Mounjaro. Wegovy will be rolled out as a once-weekly injectable, delivered via a FlexTouch pen-like device—a user-friendly, self-administered format that eliminates the need for vials or syringes. The drug is expected to be available in Indian pharmacies by the end of June 2025, according to Vikrant Shrotriya, Managing Director of Novo Nordisk India. A market ripe for disruption Novo Nordisk is betting big on India, where nearly 254 million people live with generalized obesity and 351 million with abdominal obesity. The Danish pharma giant sees India as a key market for future sales, aiming to capture a large share of the country's ₹576 crore anti-obesity drug market, which has quadrupled from ₹133 crore in 2021, according to PharmaTrac. 'Obesity is not just a personal health concern — it is a chronic disease and a national epidemic that India cannot afford to ignore,' said Shrotriya. 'We are bringing Wegovy with the convenience of a world-class, state-of-the-art pen device, and an India-specific price.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Source: iStock How Wegovy works: Science behind the shot Wegovy contains semaglutide, a GLP-1 receptor agonist, which mimics a natural hormone responsible for regulating blood sugar, reducing appetite, delaying gastric emptying, and improving satiety. While related drugs like Ozempic are used primarily for type 2 diabetes, Wegovy is specifically approved for chronic weight management in cases of morbid obesity. The FlexTouch device allows patients to dial in their weekly dose, with four needles included in each monthly pack. The drug works on key centers of the brain that regulate hunger and food cravings, promoting weight loss while offering additional metabolic benefits. According to diabetologist Dr. V. Mohan, 'Clinical data on semaglutide demonstrates not just weight loss but also considerable improvement in cardiovascular risk factors and inflammatory markers. For Indians, where diabetes and heart disease are on the rise, access to such evidence-based therapy offers holistic benefits.' India-specific pricing for Wegovy: Full dose list With a pricing strategy tailored for the Indian market, Novo Nordisk is offering the same cost for the initial three dosing strengths: Dose Monthly Price (₹) Per Dose (₹) 0.25 mg ₹17,345 ₹4,366 0.5 mg ₹17,345 ₹4,366 1 mg ₹17,345 ₹4,366 1.75 mg ₹24,280 ₹6,070 2.4 mg ₹26,015 ₹6,503 By comparison, Mounjaro, which contains the dual-action compound tirzepatide, is priced more competitively: Source: iStock Mounjaro Dose Monthly Price (₹) 2.5 mg ₹14,000 5 mg ₹17,500 Results comparable to bariatric surgery — but with caveats Wegovy has demonstrated remarkable outcomes in clinical studies, positioning it as a breakthrough in the treatment of obesity and related conditions. Patients using the drug experienced an average weight loss of nearly 15%, with one in three shedding as much as 20% of their body weight. Beyond weight loss, Wegovy also significantly reduces the risk of major cardiovascular events such as heart attacks and strokes. The drug also had notable benefits for liver health and showed improvement in liver fibrosis. However, the benefits of Wegovy are tied closely to continued use. Discontinuation often results in weight regain, and medical experts have raised concerns about potential muscle mass loss over time, underscoring the need for long-term management and monitoring. Wegovy vs. Mounjaro: Key differences Aspect Wegovy (Semaglutide) Mounjaro (Tirzepatide) Mechanism GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist Effect Reduces appetite, delays gastric emptying Enhances insulin secretion, appetite suppression Indication Approved for weight loss Approved for diabetes, used off-label for weight loss Dosing Once a week via Flexpen Once a week via single-dose vials Price ₹17,345–₹26,015 per month ₹14,000–₹17,500 per month One step to a healthier you—join Times Health+ Yoga and feel the change
Time of India
2 hours ago
- Time of India
Officials: Chaibasa study shows 78% recovery rate in malnourished kids
1 2 Ranchi: A nutrition intervention piloted in Chaibasa (West Singhbhum) has demonstrated a promising 78% recovery rate among children suffering from Severe Acute Malnutrition (SAM), signalling potential for a scalable solution to the state's ongoing child malnutrition crisis. The results were presented on Tuesday at a state-level dissemination programme held at Rajendra Institute of Medical Sciences (Rims) to assess the impact of the augmented Take-Home Ration (THR), known as 'Shishu Shakti.' The supplementary food product was developed in collaboration with the National Institute of Nutrition (NIN), Hyderabad, under the Strategic Action for Alleviation of Malnutrition and Anaemia Reduction (SAAMAR) programme. You Can Also Check: Ranchi AQI | Weather in Ranchi | Bank Holidays in Ranchi | Public Holidays in Ranchi The pilot study was conducted in the Chakradharpur block of West Singhbhum district from January to May 2025, enrolling 139 children diagnosed with SAM. Of the 124 children who completed the intervention, 97 (78%) achieved recovery. The ready-to-eat formulation offers nutritional value, providing 490 kilocalories and 17 grams of protein per 100 grams, compared to 455 kilocalories and 12.7 grams of protein in the standard Take-Home Ration. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like A severe blood disorder has put her life at risk! Donate For Health Donate Now Director of social welfare, Kiran Kumari Passi said, "The pilot was implemented in one of the most difficult districts in terms of terrain and economic development. Understanding community-specific challenges is essential. Factors such as low milk consumption, alcoholism, child marriage, and high dropout rates among girls leading to low maternal education directly impact child nutrition." Palamu DC, Sameera S, stated, "Training of master trainers at the state and district levels has been completed, and block-level training of ASHAs and Anganwadi workers is underway. We anticipate expanding Shishu Shakti across Palamu shortly."
